4004:TSEResonac Holdings Corporation Analysis

Current price SAR 112.2 sits just above the 20‑day SMA (108.6) but below the 50‑day SMA (116.7), indicating a short‑term pull‑back within a broader bearish bias (trend_direction: bearish). The MACD histogram is positive and the MACD signal is flagged bullish, while RSI hovers around 50.7, suggesting neither overbought nor oversold conditions. Volatility is elevated at 38% over the past 30 days and beta is essentially neutral (‑0.02), meaning price swings are driven more by company‑specific factors than market movements. The Fear & Greed Index sits at 72.9 (“Greed”), reflecting a market appetite for risk despite the technical downside.
Fundamentally, Dallah Healthcare shows robust revenue growth of 25% YoY and a PE of 20.8, well below the industry average of 26.2, hinting at relative undervaluation. However, the DCF fair value (SAR 104) is below the current market price, and a high debt‑to‑equity ratio (74%) combined with negative free cash flow raises sustainability concerns. The dividend yield of 1.78% with a 37% payout ratio is modest, and the recent cash dividend announcement (0.50 SAR, ex‑date Mar 25) provides a short‑term boost but may strain cash resources. Overall, the stock appears fairly priced with a blend of growth and value characteristics, but financial leverage and cash flow constraints temper optimism.